Abstract Number: 694 • 2016 ACR/ARHP Annual Meeting
Diagnostic Delay Leads to Worse Response to Treatment
Is there a clinical patient profile for PsA Patients with a diagnostic delay? Background/Purpose: Psoriatic arthritis (PsA) is a progressive inflammatory musculoskeletal disease. Several recent…Abstract Number: 695 • 2016 ACR/ARHP Annual Meeting
Secukinumab Sustains Individual Clinical Responses over Time in Patients with Active Ankylosing Spondylitis: 2-Year Results from a Phase 3 Randomized Placebo-Controlled Trial
Background/Purpose: The assessment of achieving, maintaining, and improving clinical response to biologics in Ankylosing Spondylitis (AS) is part of treat-to-target recommendations aimed at optimizing treatment…Abstract Number: 696 • 2016 ACR/ARHP Annual Meeting
Significantly Reduced Recurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis during Treatment with Golimumab
Background/Purpose: Acute anterior uveitis (AAU) is common in ankylosing spondylitis (AS) (1). Golimumab, a tumor necrosis factor alpha (TNF-α) blocker, has proven to be effective…Abstract Number: 697 • 2016 ACR/ARHP Annual Meeting
Does Axial Spondyloarthritis Phenotype Correlate with Imaging Morphotype?
Background/Purpose: Traditionally, radiographic imaging was used to describe morphological differences between various types of axial SpA (axSpA). MRI has advanced understanding of disease, enabled earlier…Abstract Number: 698 • 2016 ACR/ARHP Annual Meeting
Performance of Modified Minimal Disease Activity (MDA) in Patients with Peripheral Spondyloarthritis
Background/Purpose: Due to lack of validated outcome measures in non-psoriatic peripheral spondyloarthritis (pSpA), recent studies in this patient (pt) population have used varying endpoints [1].…Abstract Number: 699 • 2016 ACR/ARHP Annual Meeting
In Contrast to Men, Women with Nonradiographic Axial Spondyloarthritis Have Lower Response Rates to TNF Inhibitors Than Women with Ankylosing Spondylitis
Background/Purpose: Response to tumor necrosis factor inhibition (TNFi) has been shown to be similar in nonradiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) in patients…Abstract Number: 700 • 2016 ACR/ARHP Annual Meeting
Incidence of Inflammatory Bowel Disease Events in Adalimumab (HUMIRA) Clinical Trials Across Indications
Background/Purpose: Adalimumab (ADA) is approved for treatment of Crohn’s disease (CD) and ulcerative colitis (UC); therefore, it is postulated that new onset or flare of…Abstract Number: 701 • 2016 ACR/ARHP Annual Meeting
In Patients with Ankylosing Spondylitis Treated with Adalimumab, Combination Therapy with DMARD, Increase the Serum Level of Adalimumab and Decrease Immunogenicity
Background/Purpose: In patients with rheumatoid arthritis, methotrexate (MTX), improves the clinical efficacy of anti-TNF (TNFi), among other reasons, for reducing the immunogenicity. However, there are…Abstract Number: 702 • 2016 ACR/ARHP Annual Meeting
Treatment with Golimumab or Infliximab Reduces Health Resource Utilization and Increases Work Productivity in Patients with Ankylosing Spondylitis in a Large, Prospective Real-Life Cohort
Background/Purpose: We evaluated the effect of the anti-tumor necrosis factor (TNF) agents, golimumab (GLM) and infliximab (IFX), on healthcare resource utilization (HCRU) and work productivity…Abstract Number: 703 • 2016 ACR/ARHP Annual Meeting
Performance of a New Spinal Mobility Index for Patients with Axial Spondyloarthritis
Background/Purpose: ASAS recommends using BASMI for evaluation of axial mobility in patients with Axial Spondyloarthritis (axSpA). The EDASMI (Edmonton Ankylosing Spondylitis Metrology Index) is another…Abstract Number: 704 • 2016 ACR/ARHP Annual Meeting
Does Change in Disease Activity over One Year Result in Change in Health-Related Quality of Life in Early Axial Spondyloarthritis Patients?
Background/Purpose: In axial Spondyloarthritis (axSpA), treatment is targeted at reducing disease activity with the aim of improving the health-related quality of life (HRQoL). Therefore, it…Abstract Number: 705 • 2016 ACR/ARHP Annual Meeting
Is a Positive Family History of Spondyloarthritis of Value in Patients with Chronic Back Pain? Results from Two Large Early Back Pain Cohorts
Background/Purpose: To assess whether presence of spondyloarthritis (SpA) manifestations in first- and second-degree relatives of patients with chronic back pain (CBP) is associated with higher…Abstract Number: 706 • 2016 ACR/ARHP Annual Meeting
Performance of the ASAS Classification Criteria for Axial and Peripheral Spondyloarthritis – a Systematic Literature Review and Meta-Analysis
Background/Purpose: The Assessment of SpondyloArthritis international Society (ASAS) has developed and validated classification criteria for axial spondyloarthritis (axSpA) and peripheral SpA (pSpA). Following their release,…Abstract Number: 707 • 2016 ACR/ARHP Annual Meeting
Anti-TNF Drugs Are Not Associated with Increasead Risk of Hzv Infections in Patients with Spondyloarthritis (SpA): Results from the GISEA Registry
Background/Purpose: Herpes zoster virus (HZV) reactivation disproportionately affects patients with systemic rheumatic diseases and it is commonly described in short- and long-term use of anti-Tumor…Abstract Number: 708 • 2016 ACR/ARHP Annual Meeting
Development of Spondyloarthritis-Features in Patients with Chronic Back Pain over a One-Year Course: Data from the Spondyloarthritis Caught Early (SPACE)-Cohort
Background/Purpose: Little is known on the development of spondyloarthritis (SpA)-features over time in patients with recent onset chronic back pain (CBP). The aim was to…
ACR Meeting Abstracts